Larvol Delta - BioSig-subsidiary-ViralClear-submits-Investigational-New-Drug-application-to-the-FDA-for-phase-II-clinical-trials-for-merimepodib-an-orally-administered-treatment-for-patients-with-Covid19

Vicromax (merimepodib) - BioSig Tech

http://www.globenewswire.com/news-release/2020/04/24/2021733/0/en/BioSig-Subsidiary-ViralClear-Submits-Investigational-New-Drug-Application-to-the-FDA-for-Phase-II-Clinical-Trials-for-Merimepodib-an-Orally-Administered-Treatment-for-Patients-with.html

Apr 24, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next